HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions

Epidemics

Volumn 2, Issue 1, 2010, Pages 21-28

  Baussano, Iacopo ^a,b   Ronco, Guglielmo ^c   Segnan, Nereo ^c   French, Katherine ^a   Vineis, Paolo ^a   Garnett, Geoff P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CPO Piemonte   (Italy)

^c CPO Piemonte   (Italy)

Author keywords

Cervical cancer; Human papillomavirus; Mathematical modeling; Screening

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CANCER CONTROL; CANCER INVASION; CLEARANCE; DISEASE COURSE; DISEASE DURATION; DYNAMICS; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; ITALY; MATHEMATICAL MODEL; NONHUMAN; PARAMETER; PRECANCER; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUALITY; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS TRANSMISSION;

ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; ITALY; MIDDLE AGED; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, VIRAL; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 77950626560     PISSN: 17554365     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.epidem.2010.02.002     Document Type: Article

References (65)

1. AIRTUM Working Group. I tumori in Italia, rapporto 2007: Sopravvivenza. Epidemiol. Prev. 31 (2007) S1-S95
2. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 3 5 (2006) e138
3. Bontkes H.J., de Gruijl T.D., Walboomers J.M., Schiller J.T., Dillner J., Helmerhorst T.J., Verheijen R.H., Scheper R.J., and Meijer C.J. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia: II. Systemic but not local IgA responses correlate with clearance of HPV-16. J. Gen. Virol. 80 Pt 2 (1999) 409-417
4. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 4 (2002) 244-265
5. Burchell A.N., Richardson H., Mahmud S.M., Trottier H., Tellier P.P., Hanley J., Coutlee F., and Franco E.L. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am. J. Epidemiol. 163 6 (2006) 534-543
6. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., and Galloway D.A. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181 6 (2000) 1911-1919
7. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C., Sherman M.E., Wacholder S., Tarone R., and Burk R.D. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J. Infect. Dis. 191 11 (2005) 1808-1816
8. Clayton D., and Hills D. Statistical Models in Epidemiology (1993), Oxford University Press, New York
9. CPO Piemonte. Relazione Sanitaria Sull'Oncologia in Piemonte: Aspetti Epidemiologici Relazione 2005/06 (2007). http://www.cpo.it/dationcologici/relsan06/capitolo1.pdf http://www.cpo.it/dationcologici/relsan06/capitolo1.pdf
10. de Gruijl T.D., Bontkes H.J., Walboomers J.M., Schiller J.T., Stukart M.J., Groot B.S., Chabaud M.M., Remmink A.J., Verheijen R.H., Helmerhorst T.J., Meijer C.J., and Scheper R.J. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 89 9 (1997) 630-638
11. de Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N., and Bosch F.X. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7 7 (2007) 453-459
12. Derhovanessian E., Solana R., Larbi A., and Pawelec G. Immunity, ageing and cancer. Immun. Ageing 5 (2008) 11
13. Frazer I.H. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384 2 (2009) 410-414
14. Galvin G.A., Jones H.W., and Te Linde R.W. The significance of basal-cell hyperactivity in cervical biopsies. Am. J. Obstet. Gynecol. 70 4 (1955) 808-821
15. Garnett G.P., and Anderson R.M. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IMA J. Math. Appl. Med. Biol. 11 3 (1994) 161-192
16. Giuliano A.R., Harris R., Sedjo R.L., Baldwin S., Roe D., Papenfuss M.R., Abrahamsen M., Inserra P., Olvera S., and Hatch K. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J. Infect. Dis. 186 4 (2002) 462-469
17. Goldhaber-Fiebert J.D., Stout N.K., Ortendahl J., Kuntz K.M., Goldie S.J., and Salomon J.A. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul. Health Metr. 5 (2007) 11
18. Gustafsson L., Ponten J., Bergstrom R., and Adami H.O. International incidence rates of invasive cervical cancer before cytological screening. Int. J. Cancer 71 2 (1997) 159-165
19. Herrero R., Castle P.E., Schiffman M., Bratti M.C., Hildesheim A., Morales J., Alfaro M., Sherman M.E., Wacholder S., Chen S., Rodriguez A.C., and Burk R.D. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J. Infect. Dis. 191 11 (2005) 1796-1807
20. Ho G.Y., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338 7 (1998) 423-428
21. Ho G.Y., Studentsov Y.Y., Bierman R., and Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol. Biomark. Prev. 13 1 (2004) 110-116
22. Holowaty P., Miller A.B., Rohan T., and To T. Natural history of dysplasia of the uterine cervix. J. Natl. Cancer Inst. 91 3 (1999) 252-258
23. International Agency for Research on Cancer. Handbooks of Cancer Prevention, vol 9. Cervix Cancer Screening (2004), IARC Press, Lyon
24. Jit M., Choi Y.H., and Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337 (2008) a769
25. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., Rush B.B., Glass A.G., and Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 14 (2005) 1072-1079
26. Kim J.J., Andres-Beck B., and Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br. J. Cancer 97 9 (2007) 1322-1328
27. Kim J.J., Kuntz K.M., Stout N.K., Mahmud S., Villa L.L., Franco E.L., and Goldie S.J. Multiparameter calibration of a natural history model of cervical cancer. Am. J. Epidemiol. 166 2 (2007) 137-150
28. Koshiol J.E., Schroeder J.C., Jamieson D.J., Marshall S.W., Duerr A., Heilig C.M., Shah K.V., Klein R.S., Cu-Uvin S., Schuman P., Celentano D., and Smith J.S. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int. J. Cancer 119 7 (2006) 1623-1629
29. Luthra U.K., Prabhakar A.K., Seth P., Agarwal S.S., Murthy N.S., Bhatnagar P., Das D.K., and Sharma B.K. Natural history of precancerous and early cancerous lesions of the uterine cervix. Acta Cytol. 31 3 (1987) 226-234
30. Mandelblatt J.S., Lawrence W.F., Womack S.M., Jacobson D., Yi B., Hwang Y.T., Gold K., Barter J., and Shah K. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287 18 (2002) 2372-2381
31. Mayrand M.H., Coutlee F., Hankins C., Lapointe N., Forest P., de Ladurantaye M., and Roger M. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J. Clin. Microbiol. 38 9 (2000) 3388-3393
32. McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., and Skegg D.C. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9 5 (2008) 425-434
33. Melnikow J., Nuovo J., Willan A.R., Chan B.K., and Howell L.P. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol. 92 4 Pt 2 (1998) 727-735
34. Moscicki A.B., Shiboski S., Hills N.K., Powell K.J., Jay N., Hanson E.N., Miller S., Canjura-Clayton K.L., Farhat S., Broering J.M., and Darragh T.M. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364 9446 (2004) 1678-1683
35. Munoz N., Mendez F., Posso H., Molano M., van den Brule A.J., Ronderos M., Meijer C., and Munoz A. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis. 190 12 (2004) 2077-2087
36. Murthy N.S., Sardana S., Narang N., Agarwal S.S., Sharma S., and Das D.K. Biological behaviour of moderate dysplasia-a prospective study. Indian J. Cancer 33 1 (1996) 24-30
37. Myers E.R., McCrory D.C., Nanda K., Bastian L., and Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol. 151 12 (2000) 1158-1171
38. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12 2 (1993) 186-192
39. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 2 (2005) 74-108
40. Peto J., Gilham C., Fletcher O., and Matthews F.E. The cervical cancer epidemic that screening has prevented in the UK. Lancet 364 9430 (2004) 249-256
41. Pett M.R., Alazawi W.O., Roberts I., Dowen S., Smith D.I., Stanley M.A., and Coleman N. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res. 64 4 (2004) 1359-1368
42. Plummer M., Schiffman M., Castle P.E., Maucort-Boulch D., and Wheeler C.M. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 195 11 (2007) 1582-1589
43. Richardson H., Kelsall G., Tellier P., Voyer H., Abrahamowicz M., Ferenczy A., Coutlee F., and Franco E.L. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomark. Prev. 12 6 (2003) 485-490
44. Rodriguez A.C., Schiffman M., Herrero R., Wacholder S., Hildesheim A., Castle P.E., Solomon D., and Burk R. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J. Natl. Cancer Inst. 100 7 (2008) 513-517
45. Ronco G., Segnan N., Giordano L., Pilutti S., Senore C., Ponti A., and Volante R. Interaction of spontaneous and organised screening for cervical cancer in Turin, Italy. Eur. J. Cancer 33 8 (1997) 1262-1267
46. Ronco G., Pilutti S., Patriarca S., Montanari G., Ghiringhello B., Volante R., Giordano L., Zanetti R., Mancini E., and Segnan N. Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992-98. Br. J. Cancer 93 3 (2005) 376-378
47. Ronco G., Giorgi-Rossi P., Carozzi F., Dalla Palma P., Del Mistro A., De Marco L., De Lillo M., Naldoni C., Pierotti P., Rizzolo R., Segnan N., Schincaglia P., Zorzi M., Confortini M., and Cuzick J. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 7 7 (2006) 547-555
48. Ronco G., Segnan N., Giorgi-Rossi P., Zappa M., Casadei G.P., Carozzi F., Dalla Palma P., Del Mistro A., Folicaldi S., Gillio-Tos A., Nardo G., Naldoni C., Schincaglia P., Zorzi M., Confortini M., and Cuzick J. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl. Cancer Inst. 98 11 (2006) 765-774
49. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 9590 (2007) 890-907
50. Schlecht N.F., Platt R.W., Duarte-Franco E., Costa M.C., Sobrinho J.P., Prado J.C., Ferenczy A., Rohan T.E., Villa L.L., and Franco E.L. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 95 17 (2003) 1336-1343
51. Signorelli C., and Colzani E. Age at first intercourse and HPV immunization. J. Prev. Med. Hyg. 48 2 (2007) 37-38
52. Signorelli C., Pasquarella C., Limina R.M., Colzani E., Fanti M., Cielo A., Greco M., de' Somenzi C.P., Chironna M., and Quarto M. Third Italian national survey on knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health education campaigns. Eur. J. Public Health 16 5 (2006) 498-504
53. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., and Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121 3 (2007) 621-632
54. Terry G., Ho L., and Cuzick J. Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type. Int. J. Cancer 73 5 (1997) 651-655
55. Trottier H., and Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 24 Suppl 1 (2006) S1-S15
56. Van de Velde N., Brisson M., and Boily M.C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am. J. Epidemiol. 165 7 (2007) 762-775
57. van Oortmarssen G.J., and Habbema J.D. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br. J. Cancer 64 3 (1991) 559-565
58. Wheeler C.M., Hunt W.C., Schiffman M., and Castle P.E. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J. Infect. Dis. 194 9 (2006) 1291-1299
59. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S.K., Kuypers J.M., and Koutsky L.A. Development and duration of human papillomavirus lesions, after initial infection. J. Infect. Dis. 191 5 (2005) 731-738
60. Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., Yates M., Rollason T.P., and Young L.S. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 9271 (2001) 1831-1836
61. Woodman C.B., Collins S.I., and Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7 1 (2007) 11-22
62. Xi L.F., Carter J.J., Galloway D.A., Kuypers J., Hughes J.P., Lee S.K., Adam D.E., Kiviat N.B., and Koutsky L.A. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol. Biomark. Prev. 11 4 (2002) 343-351
63. Ylitalo N., Josefsson A., Melbye M., Sorensen P., Frisch M., Andersen P.K., Sparen P., Gustafsson M., Magnusson P., Ponten J., Gyllensten U., and Adami H.O. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res. 60 21 (2000) 6027-6032
64. Ylitalo N., Sorensen P., Josefsson A.M., Magnusson P.K., Andersen P.K., Ponten J., Adami H.O., Gyllensten U.B., and Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355 9222 (2000) 2194-2198
65. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 5 (2002) 342-350